LUX 2TIRZ

Tirzepatide is a dual GIP/GLP-1 receptor agonist studied in metabolic and obesity research. Published clinical literature and FDA-approved labeling support its role in glucose regulation, appetite-related pathways, and body-weight management. It is a peptide with established clinical and regulatory relevance in specific approved settings.

What tirzepatide has been studied for

• glucose regulation in type 2 diabetes
• appetite and energy-intake signaling
• chronic weight management
• obesity-related metabolic outcomes
• obstructive sleep apnea in adults with obesity

Current approved uses

• Mounjaro: used with diet and exercise to improve blood sugar in adults and children age 10 and older with type 2 diabetes.
• Zepbound: approved for chronic weight management in adults with obesity, or adults with overweight plus at least one weight-related condition, alongside reduced-calorie diet and increased physical activity.
• Zepbound: also approved for moderate to severe obstructive sleep apnea in adults with obesity.

Relevant source
Zepbound (tirzepatide). It documents the approved indications, boxed warning, and use in chronic weight management and OSA